These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33590464)

  • 1. Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy.
    Al-Zubaydi F; Gao D; Kakkar D; Li S; Holloway J; Szekely Z; Chan N; Kumar S; Sabaawy HE; Love S; Sinko PJ
    Drug Deliv Transl Res; 2022 Jan; 12(1):240-256. PubMed ID: 33590464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy.
    Al-Zubaydi F; Gao D; Kakkar D; Li S; Adler D; Holloway J; Szekely Z; Gu Z; Chan N; Kumar S; Love S; Sinko PJ
    J Control Release; 2020 Jul; 323():71-82. PubMed ID: 32302762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of size and polymer architecture of doxorubicin-poly(ethylene) glycol conjugate nanocarriers on breast duct retention, potency and toxicity.
    Gu Z; Gao D; Al-Zubaydi F; Li S; Singh Y; Rivera K; Holloway J; Szekely Z; Love S; Sinko PJ
    Eur J Pharm Sci; 2018 Aug; 121():118-125. PubMed ID: 29698706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraductal therapy of ductal carcinoma in situ: a presurgery study.
    Mahoney ME; Gordon EJ; Rao JY; Jin Y; Hylton N; Love SM
    Clin Breast Cancer; 2013 Aug; 13(4):280-6. PubMed ID: 23664819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraductal delivery of nanocarriers for ductal carcinoma
    Pandey M; Wen PX; Ning GM; Xing GJ; Wei LM; Kumar D; Mayuren J; Candasamy M; Gorain B; Jain N; Gupta G; Dua K
    Nanomedicine (Lond); 2022 Oct; 17(24):1871-1889. PubMed ID: 36695306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraductal Drug Delivery to the Breast: Effect of Particle Size and Formulation on Breast Duct and Lymph Node Retention.
    Joseph MK; Islam M; Reineke J; Hildreth M; Woyengo T; Pillatzki A; Baride A; Perumal O
    Mol Pharm; 2020 Feb; 17(2):441-452. PubMed ID: 31886676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs.
    Weir SJ; Wood R; Schorno K; Brinker AE; Ramamoorthy P; Heppert K; Rajewski L; Tanol M; Ham T; McKenna MJ; McCulloch W; Dalton M; Reed GA; Jensen RA; Baltezor MJ; Anant S; Taylor JA
    J Pharmacol Exp Ther; 2019 Aug; 370(2):148-159. PubMed ID: 31113837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
    Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraductal fulvestrant for therapy of ERα-positive ductal carcinoma in situ of the breast: a preclinical study.
    Wang G; Chen C; Pai P; Korangath P; Sun S; Merino VF; Yuan J; Li S; Nie G; Stearns V; Sukumar S
    Carcinogenesis; 2019 Jul; 40(7):903-913. PubMed ID: 31046118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of intraductal delivery of poly(ethylene glycol)-doxorubicin conjugate nanocarriers for the treatment of ductal carcinoma in situ (DCIS)-like lesions in rats.
    Gu Z; Al-Zubaydi F; Adler D; Li S; Johnson S; Prasad P; Holloway J; Szekely Z; Love S; Gao D; Sinko PJ
    J Interdiscip Nanomed; 2018 Sep; 3(3):146-159. PubMed ID: 30443411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus Inhibits the Progression of Ductal Carcinoma
    Chen G; Ding XF; Pressley K; Bouamar H; Wang B; Zheng G; Broome LE; Nazarullah A; Brenner AJ; Kaklamani V; Jatoi I; Sun LZ
    Clin Cancer Res; 2020 Mar; 26(6):1486-1496. PubMed ID: 31871301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex.
    Weir SJ; Dandawate P; Standing D; Bhattacharyya S; Ramamoorthy P; Rangarajan P; Wood R; Brinker AE; Woolbright BL; Tanol M; Ham T; McCulloch W; Dalton M; Reed GA; Baltezor MJ; Jensen RA; Taylor JA; Anant S
    Cell Death Dis; 2021 May; 12(6):562. PubMed ID: 34059639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reposition of the Fungicide Ciclopirox for Cancer Treatment.
    Huang Z; Huang S
    Recent Pat Anticancer Drug Discov; 2021; 16(2):122-135. PubMed ID: 33573561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis.
    Ploumen RAW; de Mooij CM; Gommers S; Keymeulen KBMI; Smidt ML; van Nijnatten TJA
    Eur Radiol; 2023 Aug; 33(8):5423-5435. PubMed ID: 37020070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    Osdoit M; Yau C; Symmans WF; Boughey JC; Ewing CA; Balassanian R; Chen YY; Krings G; Wallace AM; Zare S; Fadare O; Lancaster R; Wei S; Godellas CV; Tang P; Tuttle TM; Klein M; Sahoo S; Hieken TJ; Carter JM; Chen B; Ahrendt G; Tchou J; Feldman M; Tousimis E; Zeck J; Jaskowiak N; Sattar H; Naik AM; Lee MC; Rosa M; Khazai L; Rendi MH; Lang JE; Lu J; Tawfik O; Asare SM; Esserman LJ; Mukhtar RA
    JAMA Surg; 2022 Nov; 157(11):1034-1041. PubMed ID: 36069821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraductal Therapy in Breast Cancer: Current Status and Future Prospective.
    Kuang XW; Liu JH; Sun ZH; Sukumar S; Sun SR; Chen C
    J Mammary Gland Biol Neoplasia; 2020 Jun; 25(2):133-143. PubMed ID: 32577880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab not for ductal carcinoma in situ?
    Nahleh Z; Namakydoust A; Bakkar R; Bishop J
    Anticancer Drugs; 2007 Nov; 18(10):1231-5. PubMed ID: 17893526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ or with locally advanced breast cancer receiving neoadjuvant chemotherapy.
    Pendas S; Jakub J; Giuliano R; Gardner M; Swor GB; Reintgen DS
    Cancer Control; 2004; 11(4):231-5. PubMed ID: 15284714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial).
    Kuo SH; Tseng LM; Chen ST; Sagara Y; Chang YC; Yeh HT; Kuo YL; Hung CC; Lu TP; Lee YH; Toi M; Huang CS
    BMC Cancer; 2023 Sep; 23(1):865. PubMed ID: 37710198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
    Ploumen RAW; Keymeulen KBMI; Kooreman LFS; van Kuijk SMJ; Siesling S; Smidt ML; van Nijnatten TJA
    Eur J Surg Oncol; 2022 Jan; 48(1):60-66. PubMed ID: 34756527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.